ERCC1 gene polymorphism in gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2014.09.008

Abstract

Abstract: As a crucial part of the DNA damage repair process, the expression of excision repair crosscomplementing group 1 (ERCC1) is closely related to the genesis and development of gastric cancer. Studies find that ERCC1 gene polymorphism can alter the expression of the gene itself, which affects the sensitivity and efficacy of platinumbased chemotherapy. Therefore, the detection of ERCC1 polymorphism may guide the individualized chemotherapy of the patients with gastric cancer.

Key words: Stomach neoplasms, Polymorphism, single nucleotide, ERCC1

Tian Yuan, Shan Zezhi, Peng Jiayuan, Wang Yu. ERCC1 gene polymorphism in gastric cancer[J]. Journal of International Oncology, 2014, 41(8): 666-668.

References

［1］ Proserpio I, Rausei S, Barzaghi S, et al. Multimodal treatment of gastric cancer［J］. World J Gastrointest Surg, 2014, 6(4): 55-58. ［2］ Zaanan A, Dalban C, Emile JF, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatinbased adjuvant chemotherapy［J］. J Cancer, 2014, 5(6): 425-432. ［3］ Cui S, Jiang L. Current translational tesearch status of ERCC1 expression of nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2014, 17(5): 428-432. ［4］ Kirschner K, Melton DW. Multiple roles of the ERCC1XPF endonuclease in DNA repair and resistance to anticancer drugs［J］. Anticancer Res, 2010, 30(9): 3223-3232. ［5］ Yin M, Yan J, Martinez BE, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatinbased chemotherapies in gastric and colorectal cancer: a systemic review and metaanalysis［J］. Clin Cancer Res, 2011, 17(6): 1632-1640. ［6］ Squires MH, Fisher SB, Fisher KE, et al. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma［J］. Cancer, 2013, 119(17): 3242-3250. ［7］ Wang J, Zhou XQ, Li JY, et al. Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer［J］. Chin J Cancer Res, 2014, 26(3): 323-330. ［8］ Yamada Y, Boku N, Nishina T, et al. Impact of excision repair crosscomplementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912［J］. Ann Oncol, 2013, 24(10): 2560-2565. ［9］周倩茹, 邱红, 胡广原, 等. ERCC1和FGFR2在胃癌组织中的表达及其临床意义［J］. 肿瘤防治研究, 2012, 39(11): 1344-1348. ［10］ Doecke J, Zhao ZZ, Pandeya N, et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma［J］. Int J Cancer, 2008, 123(1): 174-180. ［11］ Hou R, Liu Y, Feng Y, et al. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use［J］. Gene, 2014, 548(1): 1-5. ［12］ Li HY, Ge X, Huang GM, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatinbased adjuvant chemotherapy in colorectal cancer in Chinese population［J］. Asian Pac J Cancer Prev, 2012, 13(7): 3465-3469. ［13］ Mazzoni F, Cecere FL, Meoni G, et al. Phase Ⅱ trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced nonsmallcell lung cancer［J］. Lung Cancer, 2013, 82(2): 288-293. ［14］ Sakano S, Ogawa S, Yamamoto Y, et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy［J］. Mol Clin Oncol, 2013, 1(3): 403-410. ［15］李师怡, 陈刚, 林贤东, 等. ERCC1基因多态性与胃癌发生发展的关系［J］. 中国肿瘤临床, 2012, 39(13): 907-910. ［16］ Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, openlabel phase 3 trial［J］. Lancet Oncol, 2013, 14(6): 490-499. ［17］ Lo Nigro C, Monteverde M, Riba M, et al. Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer［J］. Int J Oncol, 2010, 37(5): 1219-1228. ［18］ Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S1 plus cisplatin in metastatic gastric cancer patients［J］. Br J Cancer, 2011, 104(7): 1126-1134. ［19］ Rumiato E, Cavallin F, Boldrin E, et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5FUbased neoadjuvant therapy［J］. Pharmacogenet Genomics, 2013, 23(11): 597-604. ［20］ Li J, Zuo X, Lv X, et al. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population［J］. Tumour Biol, 2014, 35(8): 7569-7574.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.